- Enoumena Therapeutics and AOP Health have signed an exclusive commercialization agreement to expand Canadian institutional access to Sibboran (landiolol hydrochloride), a short-acting, selective beta-1 blocker authorized by Health Canada in 2023.
- Sibboran is indicated for short-term ventricular rate reduction in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter, in perioperative, postoperative, and other acute-care settings.
- With an elimination half-life of approximately four minutes, landiolol allows physicians to adjust heart rate control rapidly according to patients’ responses, supporting its use when precise, reversible rate control is needed.
- Under the agreement, Enoumena will lead Canadian commercialization, hospital formulary access, and medical engagement, while AOP Health will manage regulatory affairs, manufacturing, quality, pharmacovigilance, and supply.
Takeaways:
The Enoumena–AOP Health partnership could strengthen Sibboran’s position in Canada’s acute-care cardiovascular market by combining local commercialization with established manufacturing and supply capabilities. Its ultra-short half-life offers a differentiation advantage in rapid, adjustable heart-rate control, while hospital formulary access will be key to adoption against existing IV beta-blockers.
Source: Enoumena Therapeutics
